{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021213","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.348595+00:00","generated_at":"2026-06-15T05:20:22.466542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Heron Therapeutics Q1 net product sales up 26% to $29.6M; net loss narrows to $32.8M","bullets":["Net product sales $29.6M vs $23.5M in Q1 2022, driven by oncology franchise growth of 15%.","Net loss $32.8M ($0.27/share), improved from $63.9M ($0.63/share) a year ago.","Cash and investments $60.0M at March 31, 2023, down from $84.9M at Dec. 31, 2022.","Appointed Craig Collard as CEO in April; APONVIE launched in March with $0.3M initial sales.","ZYNRELEF sNDA PDUFA date set for Oct. 23, 2023; 907 unique accounts have purchased since launch."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021213","json":"https://secwatch.observer/filing/0000950170-23-021213.json","markdown":"https://secwatch.observer/filing/0000950170-23-021213.md","text":"https://secwatch.observer/filing/0000950170-23-021213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023021213/0000950170-23-021213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023021213/hrtx-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:20:22.466542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}